1. MARKETS
  2. SECTOR : HEALTHCARE
  3. INDUSTRY : HEALTHCARE SERVICES
  4. ASPIRA PATHLAB & DIAGNOSTICS LTD.
Aspira Pathlab & Diagnostics Ltd.
BSE: 540788
Ask AI about Aspira Pathlab
8,444

BSE 23 Sep, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Aspira Pathlab quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Aspira Pathlab quarterly results: revenue, profit, and P&L – 13 quarter history

  • POSITIVE

    Quarterly Revenue Aspira Pathlab Jun-2026 Quarterly Revenue is Rs 6 Cr which is growth of 17.4% YoY.

  • NEGATIVE

    Quarterly Net Profit Aspira Pathlab Jun-2026 Quarterly Net Profit is Rs -0 Cr which is growth of -108.0% YoY.

Aspira Pathlab & Diagnostics Ltd., Quarterly, standalone, All financials are in INR Cr and price data in INR
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
6.36.75.38.25.45.95.56.34.73.93.63.52.7
Operating Exp.
5.86.96.35.94.44.74.64.84.33.93.83.72.9
Operating Profit
0.3-0.3-1.22.20.81.10.81.40.4-0.1-0.4-0.4-0.3
Operating Profit Margin %
5.57%-5.11%-23.64%27.05%15.64%18.24%14.20%21.97%7.53%-3.10%-10.75%-11.10%-12.56%
Depr.
0.40.40.40.40.40.40.40.40.40.40.40.40.4
Interest
0.10.10.10.10.10.10.10.10.10.10.10.10.1
Profit Before Tax
-0-0.7-1.61.80.50.70.41-0-0.5-0.7-0.7-0.7
Tax
Net Profit
-0-0.7-1.61.80.50.70.41-0-0.5-0.7-0.7-0.7
EPS Adj. latest
-0-0.7-1.51.80.50.70.41-0-0.5-0.7-0.7-0.7
Net profit TTM
-0.50.11.53.42.62.10.9-0.3-2-2.7-2.4-1.3-0.5
Basic EPS TTM
-0.40.11.43.32.520.8-0.3-1.9-2.6-2.4-1.2-0.5
Results PDF
          
Result Notes
  
*All financials are in INR Cr and price data in INR

Aspira Pathlab competitor comparison and performance snapshot within industry

Aspira Pathlab annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

  • POSITIVE

    Annual Revenue Aspira Pathlab Mar-2026 Annual Revenue is Rs 25 Cr which is growth of 13.9% YoY.

  • NEGATIVE

    Annual Net Profit Aspira Pathlab Mar-2026 Annual Net Profit is Rs 0 Cr which is growth of -97.5% YoY.

Aspira Pathlab & Diagnostics Ltd., Annual, standalone, All financials are in INR Cr and price data in INR
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMMar '26Mar '25Mar '24Mar '23Mar '22Mar '21Mar '20Mar '19Mar '18Mar '17Mar '16
19.9%
10.6%
26.425.522.413.614.819.615.48.77.94.61.10.3
Operating Exp. Ann.
22.1%
15%
24.923.518.514.412.913.211.710.210.98.23.30.2
Operating Profit Ann.
-2.1%
-15.6%
11.53.5-1.21.66.43.5-1.8-3.3-3.9-2.6-0.2
OPM Ann. %
-18.9%
-24.1%
 5.74%15.74%-8.71%10.78%32.46%22.80%-21.00%-41.15%-84.60%-241.35%-72.39%
19.6%
12.7%
 25.520.316.314.915.21412.913.110.23.80.3
EBITDA Ann.
1.7%
-11.6%
 23.9-0.81.96.53.7-1.5-3-3.7-2.30.1
EBITDA Ann. margin %
-15.7%
-20.3%
 7.76%17.48%-5.62%12.95%32.94%24.12%-17.69%-37.94%-79.79%-212.44%27.61%
Interest Ann.
0%
-15%
0.40.40.40.40.40.40.9110.80.30.1
Depr.
-2.1%
1.4%
1.61.51.51.51.61.61.41.71.21.10.2
PBT Ann.
-
-41%
-0.50.12.1-2.7-0.14.51.4-4.2-5.2-5.6-2.70
Tax Ann.
-
-
 00
-
-41%
 0.12.1-2.7-0.14.51.4-4.2-5.2-5.6-2.70
Net Profit Ann.
-
-41%
-0.50.12.1-2.7-0.14.51.4-4.2-5.2-5.6-2.70
NPM Ann. %
-
-53.4%
 0.20%9.42%-20.23%-0.61%22.81%9.08%-50.38%-67.86%-128.10%-359.08%
EPS Adj. latest Ann.
-
-40.1%
 0.12-2.6-0.14.31.3-4.1-5-5.4-2.70
Result Notes
     
Annual Reports
  
*All financials are in INR Cr and price data in INR
Total Rev. Ann.
1Y CHG
13.8%
2Y CAGR
36.9%
3Y CAGR
19.9%
5Y CAGR
10.6%
7Y CAGR
18.2%
10Y CAGR
55.9%
Total Revenue Annual growth is stable compared to historical averages.
Net Profit Ann.
1Y CHG
-95.2%
5Y CAGR
-41%
Net Profit Annual is falling faster than historical averages.
Operating Exp. Ann.
1Y CHG
27%
2Y CAGR
27.7%
3Y CAGR
22.1%
5Y CAGR
15%
7Y CAGR
11.6%
10Y CAGR
61.1%
Operating Expenses Annual Cr growth is higher than historical averages.

Aspira Pathlab balance sheet as of Mar 2026: assets, liabilities, reserves, and borrowings – 11 year history

  • POSITIVE

    Total Shareholders Fund Aspira Pathlab Mar-2026 Total Shareholders Fund is Rs 9 Cr which is growth of 1.9% YoY.

  • POSITIVE

    Total Assets Aspira Pathlab Mar-2026 Total Assets is Rs 19 Cr which is growth of 5.7% YoY.

Aspira Pathlab & Diagnostics Ltd., Balance Sheet, standalone, All financials are in INR Cr and price data in INR
IndicatorGraphCAGR 3 YrsCAGR 5 YrsMar '26Mar '25Mar '24Mar '23Mar '22Mar '21Mar '20Mar '19Mar '18Mar '17Mar '16
3.7%
20.7%
8.78.56.37.87.93.43.85.20.35.93.6
Minority Interest Liability Ann.
-
-
-----------
-15.7%
3.7%
1.81.71.433.61.55.45.410.63.2
24.7%
9.2%
3.12.42.11.61.825.14.21.65.82.7
Total Capital Plus Liabilities Ann.
2.3%
9.4%
18.517.514.717.318.111.814.314.812.514.96.3
-3.5%
-1.6%
7.26.56.889.67.88.78.97.980
6.5%
12%
13.912.210.411.5117.911.112.510.710.90.6
-8%
3.4%
4.65.44.45.97.13.93.32.31.845.7
Total Assets Ann.
2.3%
9.4%
18.517.514.717.318.111.814.314.812.514.96.3
Contingent Liabilities plus Commitments Ann.
-
-
1.11.11.10.2
Bonus Equity Share Capital Ann.
-
-
Non Current Investments Unquoted Book Value Ann.
-
-
Current Investments Unquoted Book Value Ann.
-
-
*All financials are in INR Cr and price data in INR
Total Assets Ann.
1Y CHG
5.7%
2Y CAGR
12.2%
3Y CAGR
2.3%
5Y CAGR
9.4%
7Y CAGR
3.2%
10Y CAGR
11.4%
Total Assets Annual growth is stable compared to historical averages.
Total Current Liabilities Ann.
1Y CHG
29.2%
2Y CAGR
21.5%
3Y CAGR
24.7%
5Y CAGR
9.2%
7Y CAGR
-4.2%
10Y CAGR
1.4%
Total Current Liabilities Annual Cr growth is higher than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
2.4%
2Y CAGR
17.5%
3Y CAGR
3.7%
5Y CAGR
20.7%
7Y CAGR
7.6%
10Y CAGR
9.2%
Total ShareHolders Funds Annual growth is lower than historical averages.

Aspira Pathlab ROE, ROCE, book value, and debt-to-equity ratio as of Mar 2026 – 11 year history

  • POSITIVE

    Book Value Per Share Aspira Pathlab Mar-2026 Book Value Per Share is 7 Rs which is growth of 0.2% YoY.

  • POSITIVE

    ROE Aspira Pathlab Mar-2026 ROE is 1% which is growth of 27.7% YoY.

Aspira Pathlab & Diagnostics Ltd., Ratios, standalone, All financials are in INR Cr and price data in INR
IndicatorGraphCAGR 3 YrsCAGR 5 YrsMar '26Mar '25Mar '24Mar '23Mar '22Mar '21Mar '20Mar '19Mar '18Mar '17Mar '16
BVSH Ann.
-2.2%
16.6%
7.17.15.17.67.63.34.16.30.611.416.2
RoA Ann. %
-
-53%
0.27%11.83%-18.16%-0.51%24.58%11.72%-29.58%-35.02%-44.54%-18.33%0.43%
ROE Ann. %
-
-55.7%
0.70%28.44%-51.25%-1.13%56.73%40.80%-111.56%-99.83%-1,667.23%-46.05%0.75%
ROCE Ann. %
11.2%
-34.2%
2.86%15.98%-18.23%2.08%29.56%23.27%-34.73%-39.86%-43.84%-27.09%2.41%
           
           
           
Total Debt to Total Equity Ann.
   0.10.10.41.81.331.61.20.7
*All financials are in INR Cr and price data in INR
ROE Ann. %
1Y CHG
-97.5%
5Y CAGR
-55.7%
10Y CAGR
-0.7%
ROE Annual % is falling faster than historical averages.
RoA Ann. %
1Y CHG
-97.7%
5Y CAGR
-53%
10Y CAGR
-4.5%
RoA Annual % is falling faster than historical averages.
Current Ratio Ann.
1Y CHG
-34.8%
2Y CAGR
-15.5%
3Y CAGR
-26%
5Y CAGR
-4.6%
7Y CAGR
14%
10Y CAGR
-3.8%
Current Ratio Annual is falling faster than historical averages.

Aspira Pathlab cash flow: net, operating, investing, and financing flows as of Mar 2026 – 11 year history

  • NEGATIVE

    Cash From Operating Activity Aspira Pathlab Mar-2026 Cash From Operating Activity is Rs 1 Cr which is growth of -22.6% YoY.

  • NEGATIVE

    Net Cash Flow Aspira Pathlab Mar-2026 Net Cash Flow is Rs -0 Cr which is growth of -151.4% YoY.

Aspira Pathlab & Diagnostics Ltd., Cash Flow, standalone, All financials are in INR Cr and price data in INR
IndicatorGraphCAGR 3 YrsCAGR 5 YrsMar '26Mar '25Mar '24Mar '23Mar '22Mar '21Mar '20Mar '19Mar '18Mar '17Mar '16
-
-23.4%
1.51.91.1-025.7-1.9-3.4-4.8-1.3-0.4
Cash from Investing Act. Ann.
-
-
-0.80.10.10.2-0.5-0.10.2-2-0.8-10.1-0
Cash from Financing Act. Ann.
-
-
-1.1-1-1-0.9-1.4-2.21.33.46.58.92.6
-
-
-0.510.2-0.80.23.4-0.4-20.9-2.52.3
*All financials are in INR Cr and price data in INR
Cash from Operating Act. Ann.
1Y CHG
-21.1%
2Y CAGR
16.8%
5Y CAGR
-23.4%
Cash from Operating Activity Annual is falling faster than historical averages.

Aspira Pathlab investor presentations, annual reports, credit ratings, and earnings calls with AI summary, video, and audio access